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Antimicrobial agents used to treat infections are life-
saving. Overuse may result in more frequent adverse 
effects and emergence of multidrug-resistant microor-
ganisms. In 2016–17, we performed the second point-
prevalence survey (PPS) of healthcare-associated 
infections (HAIs) and antimicrobial use in European 
acute care hospitals. We included 1,209 hospitals and 
310,755 patients in 28 of 31 European Union/European 
Economic Area (EU/EEA) countries. The weighted prev-
alence of antimicrobial use in the EU/EEA was 30.5% 
(95% CI: 29.2–31.9%). The most common indication for 
prescribing antimicrobials was treatment of a commu-
nity-acquired infection, followed by treatment of HAI 
and surgical prophylaxis. Over half (54.2%) of antimi-
crobials for surgical prophylaxis were prescribed for 
more than 1 day. The most common infections treated 
by antimicrobials were respiratory tract infections and 
the most commonly prescribed antimicrobial agents 
were penicillins with beta-lactamase inhibitors. There 
was wide variation of patients on antimicrobials, in 
the selection of antimicrobial agents and in antimicro-
bial stewardship resources and activities across the 
participating countries. The results of the PPS provide 
detailed information on antimicrobial use in European 
acute care hospitals, enable comparisons between 
countries and hospitals, and highlight key areas for 
national and European action that will support efforts 
towards prudent use of antimicrobials.
Background
Antimicrobials are commonly used in acute care hos-
pitals for the treatment of both community-acquired 
and healthcare-associated infections (HAIs), and for 
surgical prophylaxis [1]. Studies have indicated that 
some antimicrobial use may be unnecessary and in 
instances when use is required, the selection, dose, 
route of administration and duration of treatment may 
be inappropriate [2,3]. Through selection pressure, 
antimicrobials contribute to the emergence and spread 
of antimicrobial resistance (AMR) [4]. Moreover, antimi-
crobial use has adverse consequences, including HAIs 
caused by  Clostridium difficile  [5,6], multidrug-resist-
ant organisms [7] and fungi [8].
Data on antimicrobial consumption in acute care hos-
pitals are necessary to assess the magnitude, the 
reasons and determinants of antimicrobial use and to 
inform public health policies that are promoting pru-
dent use of antimicrobials. In June 2017, the European 
Commission published the European guidelines for 
the prudent use of antimicrobials in human medicine 
[9]. These guidelines recommend establishing anti-
microbial stewardship programmes in all healthcare 
facilities. Although antimicrobial consumption in hos-
pitals is measured at a national level by some EU/EEA 
countries, methodologies are not always consistent 
between countries and therefore preclude valid com-
parisons. The European Surveillance of Antimicrobial 
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Figure 1
Indications for antimicrobial use in acute care hospitals, 28 European Union/European Economic Area countriesa and 
Serbia, 2016–2017
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czech Republic
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Luxembourg
Malta
The Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Uk-England
Uk-Scotland
EU/EEA
Uk-Wales
Serbia
0 25 50 75 100
Community infection Hospital infection
Proportion of total antimicrobial use (%)
Long-term care infection
OtherMedical prophylaxis
Unkown/missing
Surgical prophylaxis
Unknown indication
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UK: United Kingdom.
aFor the UK, data for England, Northern Ireland, Scotland and Wales are presented separately.
The three EU/EEA countries that did not participate were Denmark, Lichtenstein and Sweden.
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Figure 2
Surgical prophylaxis in acute care hospitals, by dose and duration, 28 European Union/European Economic Area countriesa 
and Serbia, 2016–2017
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Slovakia
Bulgaria
Greece
Croatia
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aFor the UK, data for England, Northern Ireland, Scotland and Wales are presented separately.
The three EU/EEA counties that did not participate were Denmark, Lichtenstein and Sweden.
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Consumption Network (ESAC-Net) monitors the use of 
antimicrobials in the EU/EEA, but does not provide uni-
form information on antimicrobial use in hospitals and 
does not include clinical data to assess the appropri-
ateness of antimicrobial prescriptions [10].
Point prevalence surveys (PPSs) are a feasible method 
to assess antimicrobial use in hospitals, and their 
value in identifying targets for interventions has been 
demonstrated [2,11]. The European Centre for Disease 
Prevention and Control (ECDC) PPS of HAIs and antimi-
crobial use in European acute care hospitals applies 
a standardised methodology for the estimation of the 
prevalence of both HAIs and antimicrobial use across 
the EU/EEA. The first ECDC PPS in 2011–12 indicated 
that 32.7% of patients in acute care hospitals received 
one or more antimicrobial agents on the day of the sur-
vey, which translated to more than 450,000 patients 
receiving at least one antimicrobial agent on any given 
day in European acute care hospitals [1].
In this study, based on data from the second PPS in 
2016–17, we aimed at estimating the prevalence of anti-
microbial use and describing the indications and the 
prescribed antimicrobial agents. Further, we aimed to 
raise awareness, identify targets for improvement and 
provide a standardised tool for evaluating the effect of 
local, regional and national policies on strengthening 
prudent use of antimicrobials in European acute care 
hospitals.
Methods
Survey design
The PPS was performed in 28 EU/EEA countries and 
one EU candidate country, Serbia. The countries were 
recommended to select the participating acute care 
hospitals by systematic random sampling. Data were 
collected by trained staff on 1 day per ward during four 
possible periods in 2016–17. The periods were selected 
to be out of the winter period (December–February) 
when antimicrobial use is the highest and out of the 
summer holiday season (July–August) when staffing at 
hospitals is usually low.
All participating countries applied a standardised pro-
tocol updated from a version used in an earlier PPS 
conducted in 2011–12 [12]; the main update was the 
addition of a larger number of structure and process 
indicators for the prevention of HAIs and for antimi-
crobial stewardship. All patients admitted to the ward 
before or at 0800 on the day of the PPS and were still 
present at the time of the PPS were included. It was 
also possible to provide aggregated denominator data 
at ward level (‘light’ protocol).
Data collection
Data collected included; hospital type and size, ward 
specialty, patient demographic data and risk factors 
and whether the patient was receiving one or more 
antimicrobial agent at the time of the PPS.
For patients receiving one or more antimicrobials 
additional data were collected for each antimicrobial 
prescribed including; the agent, the route of admin-
istration, the dosage and indication based on pre-
scriber judgement (treatment of community, hospital or 
long-term care acquired infection, surgical or medical 
prophylaxis), diagnosis by anatomical site in case of 
treatment (e.g. pneumonia, urinary tract infection etc.), 
documentation of the reason for antimicrobial prescrip-
tion in the medical records, and whether the current 
antimicrobial regimen was the same as the one that 
had been initiated. In case of change, the reason for 
change had to be indicated (escalation, de-escalation, 
switch from intravenous to oral, adverse effects, other 
or unknown).
Prevalence of antimicrobial use and the number of 
Defined Daily Doses
The 2018 version of the Anatomical Therapeutic 
Chemical/Defined Daily Dose (ATC/DDD) index of the 
World Health Organization (WHO) Collaborating Centre 
for Drug Statistics Methodology was used for calculat-
ing the prevalence of antimicrobial use and the num-
ber of DDDs per 100 patients on the day of PPS [13]. 
Antimicrobial agents for systemic use within ATC groups 
A07AA (intestinal antiinfectives), D01BA (dermatologi-
cal antifungals for systemic use), J01 (antibacterials 
for systemic use), J02 (antimycotics for systemic use), 
J04 (antimycobacterials) as second-line treatment of 
e.g. meticillin-resistant  Staphylococcus aureus  (MRSA) 
infections (rifampicin) or for treatment of mycobacteria 
other than tuberculosis (MOTT) and P01AB (nitroimida-
zole-derived antiprotozoals) were included. Antiviral 
agents and antimicrobials for the treatment of myco-
bacteria were not included. For the calculation of the 
number of DDD per 100 patients, children and adoles-
cents (< 18 years of age) and neonates were excluded, 
as DDDs are defined for adults only.
Structure and process indicators
Data on the structure and process indicators in relation 
to antimicrobial stewardship were collected at hospital 
level including; number of full-time equivalent antimi-
crobial stewardship consultants, existence of a formal 
hospital procedure for post-prescription review of the 
appropriateness of an antimicrobial within 72 hours (3 
calendar days) from the initial order and participation 
in a national or regional hospital antimicrobial con-
sumption surveillance network.
Data from the United Kingdom (UK) were reported 
separately for the four administrations: UK-England, 
UK-Northern Ireland, UK-Scotland and UK-Wales.
Descriptive analysis
All analyses were performed with R, version 3.4.0 (R 
Foundation for Statistical Computing, Vienna, Austria).
Country representativeness of the sample was consid-
ered ‘optimal’ if the recommended systematic random 
sampling of hospitals was used, ‘good’ if a sufficient 
number of representative hospitals was selected 
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applying a different methodology or ‘poor’ if there was 
no systematic selection of a representative sample 
hospitals. For countries contributing to the survey with 
more than 20,000 patients, a randomised sub-sample 
was used in the final analysis to avoid over-represen-
tation of these countries when making analyses for the 
EU/EEA overall.
The prevalence of antimicrobial use was reported as 
the percentage of patients receiving at least one anti-
microbial agent on the day of the survey. Antimicrobial 
groups and agents were classified according to the 
ATC/DDD index at the level of the chemical group 
(4th  ATC level) and the chemical substance (5th  ATC 
level). The relative frequencies of antimicrobial groups 
(4th ATC level) were calculated. In addition, the relative 
frequencies of individual antimicrobial agents (5th ATC 
level) that represented the Drug Utilisation 75% 
(DU75%), i.e. describing the agents that made 75% of 
total antimicrobial use in the participating hospitals, 
were also reported [14].
The proportion of the broad-spectrum antibacterials, 
among all antibacterials for systemic use (ATC J01), was 
also calculated – as proposed in the ECDC, European 
Food Safety Authority (EFSA) and European Medicines 
Figure 3
Antimicrobial agents (ATC code) accounting for 75% of antimicrobial use (Drug Utilisation 75%) in acute care hospitals, 
European Union/European Economic Area countries, 2016–2017
Amoxicillin and beta-lactamase inhibator (J01CR02)
Piperacillin and beta-lactamase inhibator (J01CR05)
Ceftriaxone (J01CR04)
Ciprofloxacin (J01MA02)
Cefuroxime (J01DC02)
Metronidazole (parenteral) (J01DC01)
Cefazolin (J01DB04)
Meropenem (J01 DH02)
Gentamicin (J01 GB03)
Levofloxacin (J01 MA12)
Amoxicillin (J01 CA04)
Clindamycin (J01 FA09)
Sulfamethoxazole and trimethoprim (J01EE01)
Fluconazole (J02 AC01)
Clarithromycin (J01 FA09)
Cefotaxime (J01 DD01)
Flucloxacillin (J01 CF05)
Ampicillin (J01 CA01)
Proportion of total antimicrobial (%)
0 2 4 6 8 10 12
Ampicillin and beta-lactamase inhibator (J01CR01)
Vancomycin (parenteral) (J01 XA01)
ATC: Anatomical Therapeutic Chemical.
The three EU/EEA counties that did not participate were Denmark, Lichtenstein and Sweden.
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Agency (EMA) Joint Scientific Opinion on a list of out-
come indicators for surveillance of AMR and antimi-
crobial consumption in humans and food producing 
animals [15]. The following antimicrobial groups and 
agents were included under broad-spectrum antimi-
crobials: piperacillin and beta-lactamase inhibitor (ATC 
J01CR05), third- and fourth-generation cephalosporins 
(J01DD and J01DE), monobactams (J01DF), carbapen-
ems (J01DH), fluoroquinolones (J01MA), glycopeptides 
(J01XA), polymyxins (J01XB), daptomycin (J01XX09) 
and oxazolidinones: linezolid (J01XX08) and tedizolid 
(J01XX11) [15].
Statistical analysis
Adjustment for design effect due to clustering of anti-
microbial use in the participating hospitals for estima-
tion of the confidence intervals was performed with 
the ‘survey’ package (v. 3.33–2) for analysis of complex 
survey samples in R.
Figure 4
Proportion of broad-spectrum antibacterialsa among all antibacterials for systemic use (J01), 28 European Union/European 
Economic Area countriesb and Serbia, 2016–2017
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Romania
Portugal
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Slovenia
Belgium
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Finland
Czech Republic
Estonia
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Lithuania
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Third- and fourth-generation 
cephalosporins (J01DD and J01DE) Carbapenems (J01DH)
Oxazolidinones; Linezolid and tedizolid (J01XX08 and J01XX11)
Fluoroquinolones (J01MA)
Piperacillin and beta-lactamase inhibator (J01CR05)Monobactams (J01DF)
Polymyxins (J01XB)
Glycopeptides (J01XA)
Daptomycin (J01XX09)
Proportion of broad-spectrum antimicrobials (%)
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Croatia
Luxembourg
Poland
EU/EEA
Malta
France
Germany
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Spain
Cyprus
The Netherlands
UK: United Kingdom.
aAs defined in the European Centre for Disease Prevention and Control, European Food Safety Authority and European Medicines Agency Joint 
Scientific Opinion: piperacillin and beta-lactamase inhibitor (ATC J01CR05), third- and fourth-generation cephalosporins (J01DD and J01DE), 
monobactams (J01DF), carbapenems (J01DH), fluoroquinolones (J01MA), glycopeptides (J01XA), polymyxins (J01XB), daptomycin (J01XX09) 
and oxazolidinones: linezolid (J01XX08) and tedizolid (J01XX11) [15].
bFor the UK, data for England, Northern Ireland, Scotland and Wales are presented separately.
The three EU/EEA counties that did not participate were Denmark, Lichtenstein and Sweden.
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For the calculation of the EU/EEA prevalence of anti-
microbial use, the participating countries’ prevalence 
was weighted using the number of occupied beds per 
day as estimated by the latest available Eurostat data 
[16].
For countries applying the standard protocol, a multi-
ple logistic regression model was built to predict the 
country prevalence of patients receiving one or more 
antimicrobial agents on the day of survey based on 
case-mix. The variables included in the model were 
age, sex, length of hospital stay (i.e. number of days 
up to the day of survey), McCabe score, intubation, 
presence of urinary catheter, surgery since admission, 
patient/consultant specialty, hospital type and hospi-
tal size [1].
For countries applying the ‘light’ protocol, and thus 
only submitting aggregated denominator data, the 
model included only patient/consultant specialty, hos-
pital type and hospital size.
Ethics statement
Ethical approval was at the discretion of each national 
public health and government body. All data shared 
with ECDC on patient and institutional level were 
anonymous.
Results
In total, 1,753 hospitals from 29 countries partici-
pated in the PPS, of which two countries, Germany and 
Norway, provided aggregated denominator data on a 
ward level. The representativeness of the sample was 
optimal in 17 countries, good in 10 countries and poor 
in two countries (Bulgaria and the Netherlands). After 
adjustment for over-representation of countries con-
tributing to the PPS with more than 20,000 patients, 
325,737 patients from 1,275 hospitals remained in the 
dataset used for this analysis.
Pooled results were only reported for the EU/EEA cor-
responding to 310,755 patients from 1,209 hospitals. 
Of these, 357 (29.5%) were primary care hospitals, 414 
(34.2%) were secondary care hospitals, 245 (20.3%) 
were tertiary care hospitals and 165 (13.6%) were spe-
cialised hospitals. The hospital type was unknown for 
28 (2.3%) hospitals.
Prevalence of antimicrobial use
Among all patients, 102,093 (32.9%) received at least 
one antimicrobial agent. Among these, 72,094 (70.6%) 
received one antimicrobial agent, 24,091 (23.6%) 
received two, 4,631 (4.5%) received three, and 1,277 
(1.3%) received four or more antimicrobial agents (max-
imum eight). In total, 139,609 prescribed antimicrobial 
agents were recorded. The overall weighted prevalence 
of antimicrobial use in EU/EEA countries was 30.5% 
(range 15.9–55.6%) (Table 1). Antimicrobials for sys-
temic use (J01) accounted for 128,881 (92.3%) pre-
scriptions, antimycotics for systemic use (J02) for 
4,425 (3.2%), antimycobacterials (J04) as second-line 
treatment of e.g. MRSA infections (rifampicin) or for 
treatment of mycobacteria other than tuberculosis 
(MOTT) for 2,315 (1.7%), nitroimidazole-derived anti-
protozoals (P01AB) for 2,113 (1.5%), intestinal antiin-
fectives (A07AA) for 1,857 (1.3%) and dermatological 
antifungals for systemic use (D01BA) for 18 (1.3%). 
Most antimicrobial agents (101,638 prescriptions, 
72.8%) were administered parenterally, 37,530 (26.9%) 
orally, 266 (0.2%) by inhalation, and 175 (0.1%) by 
other routes. The reason for prescribing the antimicro-
bial was documented in the patient’s medical records 
for 112,033 (80.2%) prescriptions.
Indications for antimicrobial use
Of 139,609 antimicrobial agents prescribed, 98,986 
(70.9%) were for treatment of infection and of these 
69.8% were prescribed for the treatment of a commu-
nity-acquired infection (Figure 1). The most common 
site of infection was the respiratory tract (31.8%), fol-
lowed by systemic infections (14.7%), the urinary tract 
(13.9%) and the gastrointestinal tract (13.6%). Other 
body sites accounted for 26.0% of the site of infection 
for antimicrobial treatment.
The proportion of antimicrobial agents prescribed for 
prophylaxis was 24.9%. More than half (10,741/19,798, 
54.2%) of surgical prophylaxis courses were prescribed 
for more than 1 day (country range 19.8–95.0%) (Figure 
2).
Most commonly used antimicrobial agents
The antimicrobial agents that accounted for 75% 
of total antimicrobial use (DU75%) are presented 
in  Figure 3. Antimicrobial prescription varied by indi-
cation. Of 27,324 antimicrobial prescriptions used for 
the treatment of HAIs, combination of penicillins with 
beta-lactamase inhibitors (J01CR) were the antimicro-
bial agents most commonly used (19.8%) followed by 
carbapenems (J01DH) and fluoroquinolones (J01MA) 
with 9.9% and 9.4%, respectively. 
Of 69,067 antimicrobial prescriptions for the treat-
ment of community-acquired infections, the three 
antimicrobial agents most commonly prescribed were 
combinations of penicillins and beta-lactamase inhibi-
tors (J01CR: mainly amoxicillin and beta-lactamase 
inhibitor, J01CR02, and piperacillin and beta-lactamase 
inhibitor, J01CR05) followed by third-generation cepha-
losporins (J01DD) and fluoroquinolones (J01MA) with 
23.2%, 11.7% and 11.1%, respectively.
Of 19,798 antimicrobial prescriptions for surgical 
prophylaxis, the three most common antimicrobial 
agents were first-generation cephalosporins (J01DB), 
second-generation cephalosporins (J01DC) and com-
binations of penicillins with beta-lactamase inhibitors 
(J01CR), with 26.6%, 17.9% and 15.1%, respectively. The 
proportion of broad-spectrum antibacterials among all 
antibacterials for systemic use (J01) is shown in Figure 
4.
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Figure 5
Change of antimicrobial during the infection episode and reported reason for change, 26 European Union/European 
Economic Area countriesa and Serbia, 2016–2017
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aFor the UK, data for England, Northern Ireland and Scotland are presented separately.
Greece, Norway and UK-Wales did not collect information on change of antimicrobials.
The three EU/EEA counties that did not participate were Denmark, Lichtenstein and Sweden.
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Change of antimicrobial agent
In total, information about change of the antimicrobial 
during the infection episode was reported for 76.8% 
of antimicrobial prescriptions. For antimicrobial pre-
scriptions where the information was reported, most 
(79.0%, country range: 61.5–93.6%) had not been 
changed since the initiation of the treatment (Figure 5). 
Escalation, de-escalation and switch from intravenous 
to oral use were reported for 10.9%, 3.9%, and 4.0% 
antimicrobial prescriptions, respectively. The change 
was due to adverse effects for 0.4% and to other rea-
sons for 1.8% prescriptions.
Antimicrobial stewardship structure and 
process indicators
The median full-time equivalents for antimicrobial 
stewardship consultants per 250 beds was 0.08 (coun-
try range: 0–0.60), with 76.3% of the participating 
hospitals reporting antimicrobial use guidelines and 
54.3% reporting some dedicated time for antimicrobial 
stewardship. Among the hospitals that submitted infor-
mation on structure and process indicators for antimi-
crobial stewardship, the proportion of hospitals in the 
EU/EEA participating countries that had implemented 
a formal policy for post-prescription review in at least 
one ward was 52.5% while the proportion of hospitals 
participating in a national or regional hospital antimi-
crobial consumption surveillance network was 60.2% 
(Table 1).
Discussion
One in three patients hospitalised in acute care hospi-
tals in the EU/EEA received one or more antimicrobials 
on the day of the PPS. The majority of the antimicro-
bials were prescribed for the treatment of a commu-
nity-acquired infection. However, almost one in five 
antimicrobial prescriptions was for the treatment of a 
HAI. Prevention and control of HAIs reduces the need 
for antimicrobials and is an essential component of 
strategies to reduce unnecessary antimicrobial use. 
Antimicrobial use was similar to or lower than what was 
observed in other studies, such as the international 
PPS (range: 27.4–50.0%) [17] or the United States (US) 
2011 PPS (49.9%) [18].
About one in seven antimicrobial prescriptions was 
for surgical prophylaxis, which represented the third 
most common indication. Surgical prophylaxis is rec-
ommended for the prevention of surgical site infections 
[19,20]. For the majority of surgical procedures, one 
preoperative dose is sufficient. In this PPS, however, 
more than half of the antimicrobial courses for surgi-
cal prophylaxis lasted more than 1 day. Although this 
proportion slightly decreased since the first survey in 
2011–12 (54% vs 59%), it remains very high and out-
side the recommended duration in common with other 
studies where it ranged from 40.6% to 86.3% [17]. This 
is an important source of unnecessary use of antimicro-
bials and should be a priority target for future efforts 
on antimicrobial stewardship in many European acute 
care hospitals.
Overall, more than one in 10 antimicrobial prescrip-
tions were for medical prophylaxis. This proportion is 
higher than the proportion of medical prophylaxis in 
the international PPS (7.4%) [17] and the proportion 
of medical prophylaxis in the US 2011 PPS (6.9%) [18]. 
Given the limited number of indications for medical 
prophylaxis and that it should only be used when indi-
cated in relevant guidelines [9], a proportion of these 
prescriptions may represent antimicrobial use without 
clear indication and are therefore, unnecessary.
Pneumonia was by far the most common indication 
for antimicrobial treatment, accounting for one in four 
antimicrobials prescribed for therapeutic indications. 
Lower urinary tract infection was the second most 
frequent indication, accounting for almost one in 10 
prescribed antimicrobials for therapeutic indications. 
These results are comparable with those of the 2011–
12 survey (where 23.1% of prescriptions for therapeutic 
indications were for pneumonia and 11.1% for lower uri-
nary tract infection) and in line with the US 2011 PPS 
on antimicrobial use [18], although the proportion of 
antimicrobials for treatment of a urinary tract infection 
was slightly lower in the international PPS than in our 
survey [17].
There was considerable variability in the prevalence 
of antimicrobial use among participating countries. 
Although part of this variability may be explained by 
differences in patient case-mix and the incidence of 
HAIs, it also reflects differences in antimicrobial pre-
scription practices in acute care hospitals e.g. variation 
in the ratio between penicillins vs other beta-lactam 
antibiotics (including cephalosporins and carbap-
enems) and fluoroquinolones between participating 
countries (data not shown).
The most commonly prescribed antimicrobial agents 
were amoxicillin and beta-lactamase inhibitor, pipera-
cillin and beta-lactamase inhibitor and ceftriaxone. 
Despite extensive global shortage in 2017 [21], piper-
acillin and beta-lactamase inhibitor was the second 
most commonly used antimicrobial whereas it ranked 
fifth in the 2011–12 survey. By contrast, ciprofloxa-
cin, which was the second most commonly prescribed 
antimicrobial agent in the 2011–12 survey, ranked 
fourth in 2016–17. This decrease may reflect the anti-
microbial stewardship efforts or focused attempts to 
reduce Clostridium difficile infections. Fluoroquinolone 
and glycopeptide use was lower in the EU/EEA in 2016–
17 than reported in the US 2011 PPS where these anti-
microbials were the first and second most commonly 
prescribed ones (accounting for 14.4% and 10.8% of 
prescriptions, respectively) [18].
Among the reasons for change of antimicrobial during 
the infection episode, the proportion of de-escalation 
and switch from intravenous to oral administration var-
ied among participating countries. In several countries, 
de-escalation or switch to oral treatment was uncom-
mon. It was not possible to assess the appropriateness 
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of low proportions of change, as no information was 
collected about the reasons for continuing or changing 
antimicrobial. However, both de-escalation and switch 
to oral treatment likely reflect the result of review of 
antimicrobial treatment when microbiological informa-
tion is available, or when the condition of the patient 
improves, and are recommended measures to support 
prudent use of antimicrobials [9,22].
There was large variability among participating coun-
tries in the human resources available for antimicrobial 
stewardship as well as in the implemented antimicro-
bial stewardship strategies. For almost all participating 
countries, some hospitals had a consultant in charge 
of antimicrobial stewardship and while this is encour-
aging, considering that the majority of hospitals still 
have no or limited dedicated staff for antimicrobial 
stewardship (or access to such a consultant), promot-
ing this must be a priority in the coming years.
In this PPS, the proportion of broad-spectrum antibac-
terials among all antibacterials for systemic use, as 
proposed by the ECDC, EFSA and EMA Joint Scientific 
Opinion, reflects their level of consumption in hospitals 
and the corresponding selection pressure [15]. These 
antibacterials can be found in the ‘Watch’ and ‘Reserve’ 
groups of antimicrobials, as defined in the WHO Model 
Lists of Essential Medicines [23]. In this PPS, the pro-
portion of broad-spectrum antibacterials ranged from 
less than 20% to more than 50% depending on the 
country. This could in part be explained by the high 
prevalence of resistance among a number of reported 
microorganisms, e.g. MRSA, vancomycin-resistant 
enterococci or third-generation cephalosporin-resist-
ant Enterobacteriaceae [24]. However, many of these 
antibacterials are also associated with both emergence 
and spread of healthcare-associated  Clostridium dif-
ficile  and multidrug-resistant microorganisms and in 
particular for third-generation cephalosporins, fluoro-
quinolones and carbapenems, with the emergence of 
multidrug-resistant Gram-negative bacteria [7], which 
are currently among the most important public health 
threats related to AMR. The wide variation and some-
times extensive use of broad-spectrum antibacterials 
indicates the need to review their indications in many 
countries and hospitals. Antimicrobial stewardship 
programmes must be designed to take into account 
both the risk of emergence of AMR and patient safety. 
Ensuring that broad-spectrum antibacterials are used 
appropriately is a key element of any strategy against 
AMR.
An important indicator of the quality of antimicrobial 
prescription is the documentation of the reason for the 
prescription in the patient notes. In our survey, almost 
one in five antimicrobial prescriptions did not include 
documentation of the reason for antimicrobial prescrip-
tion. While this was lower than in the 2011–12 survey, it 
still indicates that ensuring that antimicrobial prescrip-
tions can be reviewed effectively in all cases to assess 
their appropriateness remains an ongoing challenge. 
In the US 2011 PPS, the rationale for the antimicrobial 
prescription was missing only in 6.9% of prescriptions 
[18].
The strengths of this survey are its large size and the 
use of a standardised protocol across all participating 
hospitals in 28 EU/EEA countries and Serbia. With only 
two EU/EEA countries (Bulgaria and the Netherlands) 
having provided data on a non-representative sam-
ple of acute care hospitals and two additional EU/EEA 
countries (Denmark and Sweden) having declined par-
ticipation, we believe that this PPS offers a representa-
tive picture of antimicrobial consumption in acute care 
hospitals in the EU/EEA, with meaningful benchmarks 
for participating countries and hospitals. The results 
were largely comparable to those of the 2011–12 PPS, 
which is both reassuring in terms of methodology but 
disappointing in terms of little change of antimicrobial 
prescription practice in European acute care hospitals 
in the past 5 years.
One limitation of this survey is its cross-sectional 
design, which evaluated antimicrobial use on 1 day 
only. However, this design has been shown to provide 
reliable results that can be used for identifying targets 
for intervention [2]. Moreover, the size and representa-
tiveness of the sample counterbalance this limitation. 
Another limitation is that we were not able to assess 
whether antimicrobial prescription was in line with 
existing international or national guidelines. However, 
observations such as prolonged duration of surgical 
prophylaxis as well as the high use of fluoroquinolo-
nes, third-generation cephalosporins and carbapen-
ems, likely indicate inappropriate antimicrobial use 
that can be addressed by specific actions.
In conclusion, this second ECDC PPS of HAIs and anti-
microbial use provided representative data on anti-
microbial use in acute care hospitals across EU/EEA 
countries. These data allow for identifying targets 
for future antimicrobial stewardship interventions. 
Ultimately, these results will be helpful to promote pru-
dent use of antimicrobials at national and European 
level and contribute to the efforts to ensure that 
European patients are receiving appropriate treatment 
while at the same time minimising the risk of adverse 
effects, and the emergence and spread of AMR.
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